Bharat Immunologicals (India) Performance

BIBCL -- India Stock  

INR 13.18  0.24  1.79%

Macroaxis gives Bharat Immunologicals performance score of 0 on a scale of 0 to 100. The firm shows Beta (market volatility) of 0.1163 which signifies that as returns on market increase, Bharat Immunologicals returns are expected to increase less than the market. However during bear market, the loss on holding Bharat Immunologicals will be expected to be smaller as well.. Even though it is essential to pay attention to Bharat Immunologicals historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis philosophy in foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Bharat Immunologicals Biologicals Corp Ltd exposes twenty-one different technical indicators which can help you to evaluate its performance. Bharat Immunologicals has expected return of -1.5609%. Please be advised to confirm Bharat Immunologicals Jensen Alpha, Semi Variance and the relationship between Standard Deviation and Value At Risk to decide if Bharat Immunologicals past performance will be repeated at some point in the near future.
Horizon     30 Days    Login   to change

Bharat Immunologicals Relative Risk vs. Return Landscape

If you would invest  1,770  in Bharat Immunologicals Biologicals Corp Ltd on September 18, 2018 and sell it today you would lose (452.00)  from holding Bharat Immunologicals Biologicals Corp Ltd or give up 25.54% of portfolio value over 30 days. Bharat Immunologicals Biologicals Corp Ltd is generating negative expected returns and assumes 3.5883% volatility on return distribution over the 30 days horizon. Simply put, 32% of equities are less volatile than Bharat Immunologicals Biologicals Corp Ltd and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, Bharat Immunologicals Biologicals Corp Ltd is expected to under-perform the market. In addition to that, the company is 3.36 times more volatile than its market benchmark. It trades about -0.43 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.08 per unit of volatility.

Bharat Immunologicals Market Risk Analysis

Sharpe Ratio = -0.435
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsBIBCL

Bharat Immunologicals Relative Performance Indicators

Estimated Market Risk
 3.59
  actual daily
 
 68 %
of total potential
  
Expected Return
 -1.56
  actual daily
 
 1 %
of total potential
  
Risk-Adjusted Return
 -0.43
  actual daily
 
 1 %
of total potential
  
Based on monthly moving average Bharat Immunologicals is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bharat Immunologicals by adding it to a well-diversified portfolio.

Bharat Immunologicals Performance Rating

Bharat Immunologicals Biologicals Corp Ltd Risk Adjusted Performance Analysis

0 

Risk-Adjusted Performance

Over the last 30 days Bharat Immunologicals Biologicals Corp Ltd has generated negative risk-adjusted returns adding no value to investors with long positions.

Bharat Immunologicals Alerts

Equity Alerts and Improvement Suggestions

Bharat Immunologicals generates negative expected return over the last 30 days
Bharat Immunologicals has high historical volatility and very poor performance
The company reported revenue of 347.99 M. Net Loss for the year was (51.73 M) with profit before overhead, payroll, taxes, and interest of 48.93 M.
Check also Trending Equities. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com